Here's Why Medtronic (MDT) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic: A Dividend Aristocrat Powering Up for 2025 and Beyond
Medtronic's NYSE: MDT share price is down significantly from its peak in 2021, providing investors a deep-value opportunity. The stock price is down because of the post-COVID correction and headwinds leading to sluggish growth, which are factors that will not last forever.
Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing
Medtronic plc reported Q2 earnings today, with revenues of $8.4bn, up 5% year-on-year, adjusted EPS of $1.26, supported by a dividend yielding 3.2%. Despite consistent mid-single-digit revenue growth and new product launches, Medtronic's share price remains flat due to unpredictable net income and modest innovation. CEO Geoff Martha highlighted strong performance and innovation in key fields such as diabetes and hypertension, but stopped short of providing specific long-term growth guidance, keeping market sentiment lukewarm.
Gold Moves Higher; Medtronic Posts Upbeat Results
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.
Medtronic plc (MDT) Q2 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q2 2025 Earnings Conference Call November 19, 2024 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Gary Corona - Interim CFO Brad Welnick - VP, IR Que Dallara - EVP and President, Diabetes Operating Unit Sean Salmon - EVP and President, Cardiovascular Portfolio Mike Marinaro - EVP and President, Medical Surgical Portfolio and Surgical Operating Unit Brett Wall - EVP and President, Neuroscience Conference Call Participants Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Pito Chickering - Deutsche Bank Anthony Petrone - Mizuho Securities Rich Newitter - Truist Securities Danielle Antalffy - UBS Joanne Wuensch - Citi Matt Miksic - Barclays Patrick Wood - Morgan Stanley Ryan Weispfenning Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations and I appreciate that you're joining us for our Fiscal '25 Second Quarter Video Earnings Webcast.
Medtronic Q2 Earnings and Revenues Top, Stock Down on Trimmed '25 View
MDT delivers diversified growth across all its segments in the second quarter of fiscal 2025.
Compared to Estimates, Medtronic (MDT) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended October 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Surpasses Q2 Earnings and Revenue Estimates
Medtronic (MDT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $1.25 per share a year ago.
Medtronic lifts annual profit view on strong demand for medical devices
Medtronic lifted the lower end of its annual profit forecast for a second time, banking on sustained demand for its medical devices in the U.S. and sending its shares up nearly 2% in premarket trading on Tuesday.
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw Medtronic (MDT) settling at $87.53, representing a +1.78% change from its previous close.
Insights Into Medtronic (MDT) Q2: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Medtronic (MDT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2024.
Beverly Hills surgeon sues Medtronic for patent infringement
A Beverly Hills surgeon is suing Medtronic claiming patent infringement of her hernia repair mesh product. It's the latest in a series of patent challenges against Medtronic.
